External Validation of Risk Scores for Predicting Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 28

PMID 39335138

Authors

Ann-Rong Yan

Desmond Yip

Gregory M Peterson

Indira Samarawickrema

Mark Naunton

Phillip Newman

Reza Mortazavi

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to evaluate the discriminatory capability of the Khorana, PROTECHT, CONKO, and COMPASS-CAT scores in ambulatory patients with lung cancer.

Methods: This retrospective cohort study included 591 patients with newly diagnosed lung cancer. A symptomatic or incidental VTE occurred in 108 patients.

Results: The Khorana score at a 2-point threshold had a discriminatory capability with an odds ratio (OR) of 1.80 and an AUC of 0.57 for 6 months, and an OR of 1.51 and an AUC of 0.55 for 12 months. The CONKO score at a 2-point threshold had a stronger discriminatory capability for both 6 months and 12 months with ORs of 3.00 and 2.13, and AUCs of 0.63 and 0.59, respectively. Additionally, higher white blood cell counts, higher neutrophil counts, hypoalbuminaemia, and not undergoing lung surgery were related to VTE occurrence ( < 0.05).

Conclusions: The Khorana score with the 2-point threshold was validated in ambulatory patients with lung cancer, with the results indicating a decline in its discriminatory capability over time (at 12 months vs. 6 months from diagnosis). The CONKO score at the original 2-point threshold showed a stronger discriminatory capability but further validation with a larger sample size is recommended. The identified predictors should be further investigated in future research.

Citing Articles

Exploration of the causal relationship and mechanisms between serum albumin and venous thrombosis: a bidirectional mendelian randomization analysis and bioinformatics study.

Xia X, Tie X, Hong M, Yin W Thromb J. 2025; 23(1):17.

PMID: 40033322 PMC: 11874119. DOI: 10.1186/s12959-025-00700-4.

References

Kuderer N, Poniewierski M, Culakova E, Lyman G, Khorana A, Pabinger I . Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). Oncologist. 2017; 23(2):247-255. PMC: 5813740. DOI: 10.1634/theoncologist.2017-0205. View

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

Howlett J, Benzenine E, Cottenet J, Foucher P, Fagnoni P, Quantin C . Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study. BMC Cancer. 2020; 20(1):461. PMC: 7245783. DOI: 10.1186/s12885-020-06930-1. View

van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M . The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. J Thromb Haemost. 2020; 18(8):1940-1951. DOI: 10.1111/jth.14824. View

Di Nisio M, van Es N, Rotunno L, Anzoletti N, Falcone L, De Tursi M . Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis. 2019; 48(1):125-133. DOI: 10.1007/s11239-019-01845-6. View

Rupa-Matysek J, Lembicz M, Rogowska E, Gil L, Komarnicki M, Batura-Gabryel H . Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018; 35(5):63. PMC: 5882764. DOI: 10.1007/s12032-018-1120-9. View

Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023; 41(16):3063-3071. DOI: 10.1200/JCO.23.00294. View

van Es N . Dynamic prediction modeling for cancer-associated venous thromboembolism. J Thromb Haemost. 2020; 18(6):1276-1277. PMC: 7317198. DOI: 10.1111/jth.14803. View

Verso M, Agnelli G, Barni S, Gasparini G, Labianca R . A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012; 7(3):291-2. DOI: 10.1007/s11739-012-0784-y. View

10.

Falanga A, Russo L, Milesi V, Vignoli A . Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017; 118:79-83. DOI: 10.1016/j.critrevonc.2017.08.003. View

11.

Yan A, Samarawickrema I, Naunton M, Peterson G, Yip D, Newman P . Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review and meta-analysis. Thromb Res. 2024; 234:120-133. DOI: 10.1016/j.thromres.2024.01.003. View

12.

Moons K, Wolff R, Riley R, Whiting P, Westwood M, Collins G . PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. Ann Intern Med. 2019; 170(1):W1-W33. DOI: 10.7326/M18-1377. View

13.

Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A . Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2018; 380(8):711-719. DOI: 10.1056/NEJMoa1814468. View

14.

Pelzer U, Sinn M, Stieler J, Riess H . [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr. 2013; 138(41):2084-8. DOI: 10.1055/s-0033-1349608. View

15.

Khorana A, Soff G, Kakkar A, Vadhan-Raj S, Riess H, Wun T . Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019; 380(8):720-728. DOI: 10.1056/NEJMoa1814630. View

16.

Mulder F, Candeloro M, Kamphuisen P, Di Nisio M, Bossuyt P, Guman N . The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019; 104(6):1277-1287. PMC: 6545838. DOI: 10.3324/haematol.2018.209114. View

17.

Konigsbrugge O, Posch F, Riedl J, Reitter E, Zielinski C, Pabinger I . Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. Oncologist. 2016; 21(2):252-7. PMC: 4746083. DOI: 10.1634/theoncologist.2015-0284. View

18.

Moik F, Chan W, Wiedemann S, Hoeller C, Tuchmann F, Aretin M . Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2020; 137(12):1669-1678. PMC: 8016631. DOI: 10.1182/blood.2020007878. View

19.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen A, Van Dreden P . Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. Oncologist. 2018; 23(11):1372-1381. PMC: 6291320. DOI: 10.1634/theoncologist.2017-0530. View

20.

Chew H, Davies A, Wun T, Harvey D, Zhou H, White R . The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008; 6(4):601-8. DOI: 10.1111/j.1538-7836.2008.02908.x. View